Prosthetic valve thrombosis (PVT) is a severe and life-threatening complication that develops after prosthetic valve implantation [1]. Surgery and thrombolytic therapy (TT) are used as effective treatment methods to treat obstructive or large non-obstructive PVT. However, TT may be contraindicated in several conditions, especially in the early postoperative period (first three weeks) or acute cerebral thromboembolism in patients with PVT. Moreover, since surgery carries a high risk in these acute situations, optimal anticoagulation with unfractionated heparin (UFH) infusion emerges as one of the appropriate treatments [2,3]. UFH treatment is recommended by the major cardiovascular guidelines in patients with obstructive PVT and suboptimal anticoagulation [4,5]. Additionally, UFH therapy and optimization of anticoagulation are considered in various clinical entities, including increased valve gradients, acute coronary syndrome, cerebrovascular accident (CVA), transient ischemic attack (TIA), and prosthetic valve endocarditis as a bridge to surgery [6]. In this single-center study, we aimed to investigate the efficacy of UFH therapy in patients with PVT who are not candidates for TT or surgery.